Mitsubishi UFJ Kokusai Asset Management Co. Ltd. boosted its holdings in shares of Zoetis Inc (NYSE:ZTS) by 1.8% in the 1st quarter, Holdings Channel.com reports. The fund owned 104,385 shares of the company’s stock after buying an additional 1,838 shares during the quarter. Mitsubishi UFJ Kokusai Asset Management Co. Ltd.’s holdings in Zoetis were worth $12,285,000 at the end of the most recent quarter.
A number of other large investors have also bought and sold shares of the business. Dundas Partners LLP lifted its stake in shares of Zoetis by 1.1% in the 4th quarter. Dundas Partners LLP now owns 81,296 shares of the company’s stock valued at $10,751,000 after purchasing an additional 900 shares during the last quarter. Camden National Bank raised its position in Zoetis by 1.3% in the fourth quarter. Camden National Bank now owns 85,178 shares of the company’s stock valued at $11,273,000 after purchasing an additional 1,080 shares during the period. Franklin Resources Inc. raised its position in Zoetis by 229.2% in the fourth quarter. Franklin Resources Inc. now owns 220,685 shares of the company’s stock valued at $29,208,000 after purchasing an additional 153,654 shares during the period. Ellevest Inc. lifted its stake in Zoetis by 54.9% during the first quarter. Ellevest Inc. now owns 590 shares of the company’s stock worth $69,000 after purchasing an additional 209 shares in the last quarter. Finally, Martingale Asset Management L P boosted its position in shares of Zoetis by 767.1% during the fourth quarter. Martingale Asset Management L P now owns 194,384 shares of the company’s stock worth $25,727,000 after buying an additional 171,967 shares during the period. Institutional investors own 91.35% of the company’s stock.
Several research firms recently issued reports on ZTS. UBS Group decreased their target price on Zoetis from $146.00 to $126.00 and set a “neutral” rating on the stock in a research note on Friday, May 8th. Citigroup reduced their price target on shares of Zoetis from $139.00 to $131.00 and set a “neutral” rating on the stock in a research report on Friday, May 8th. Goldman Sachs Group restated a “buy” rating and issued a $162.00 price objective on shares of Zoetis in a report on Friday, February 28th. Bank of America reaffirmed a “hold” rating and set a $145.00 target price on shares of Zoetis in a research note on Wednesday, February 12th. Finally, SunTrust Banks reissued a “hold” rating and issued a $145.00 price target on shares of Zoetis in a research report on Friday, February 14th. Seven equities research analysts have rated the stock with a hold rating, ten have given a buy rating and one has assigned a strong buy rating to the company. The company currently has a consensus rating of “Buy” and a consensus target price of $139.00.
In other news, EVP Roxanne Lagano sold 4,463 shares of Zoetis stock in a transaction dated Tuesday, May 19th. The stock was sold at an average price of $131.02, for a total transaction of $584,742.26. Following the sale, the executive vice president now owns 40,143 shares in the company, valued at $5,259,535.86. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through the SEC website. Also, EVP Heidi C. Chen sold 1,179 shares of the company’s stock in a transaction dated Friday, May 1st. The shares were sold at an average price of $127.44, for a total value of $150,251.76. Following the completion of the sale, the executive vice president now directly owns 17,514 shares of the company’s stock, valued at $2,231,984.16. The disclosure for this sale can be found here. Insiders have sold a total of 66,844 shares of company stock valued at $9,264,589 in the last 90 days. Insiders own 0.17% of the company’s stock.
Zoetis stock traded down $0.22 during midday trading on Friday, reaching $130.11. The company’s stock had a trading volume of 1,594,563 shares, compared to its average volume of 2,399,752. The company has a market cap of $61.90 billion, a P/E ratio of 35.13, a P/E/G ratio of 4.65 and a beta of 0.78. The company has a quick ratio of 1.91, a current ratio of 2.77 and a debt-to-equity ratio of 2.22. The business has a 50-day simple moving average of $125.87 and a 200-day simple moving average of $128.04. Zoetis Inc has a fifty-two week low of $90.14 and a fifty-two week high of $146.26.
Zoetis (NYSE:ZTS) last released its quarterly earnings data on Wednesday, May 6th. The company reported $0.95 EPS for the quarter, beating analysts’ consensus estimates of $0.86 by $0.09. The business had revenue of $1.53 billion for the quarter, compared to the consensus estimate of $1.50 billion. Zoetis had a return on equity of 67.72% and a net margin of 25.41%. The business’s revenue for the quarter was up 5.4% on a year-over-year basis. During the same quarter in the prior year, the business posted $0.88 EPS. As a group, equities analysts forecast that Zoetis Inc will post 3.32 earnings per share for the current year.
The business also recently disclosed a quarterly dividend, which will be paid on Tuesday, September 1st. Shareholders of record on Friday, July 17th will be issued a dividend of $0.20 per share. The ex-dividend date is Thursday, July 16th. This represents a $0.80 dividend on an annualized basis and a yield of 0.61%. Zoetis’s payout ratio is currently 21.98%.
Zoetis Inc discovers, develops, manufactures, and commercializes animal health medicines, vaccines, and diagnostic products in the United States and internationally. It commercializes products primarily across species, including livestock, such as cattle, swine, poultry, fish, and sheep; and companion animals comprising dogs, cats, and horses.
Featured Story: Using other technical indicators with support levels
Want to see what other hedge funds are holding ZTS? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Zoetis Inc (NYSE:ZTS).
Receive News & Ratings for Zoetis Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Zoetis and related companies with MarketBeat.com's FREE daily email newsletter.